Why I'm Not Writing About GLP-1 and Skin Yet. My Op-Ed on Evidence Patience

This week's intelligence review flagged a new signal on GLP-1 medications and dermatologic effects, then deliberately did not turn it into an article. I want to explain why, because I think the decision not to write something is as editorially meaningful as the decision to write it, and it is a decision most content operations never explain out loud.

Why a single signal is not yet an article

A single new report, even a legitimate one, describes an association or an early finding — not a settled clinical picture. Writing a confident-sounding article off one early signal risks two failure modes I actively try to avoid: overstating certainty the evidence does not support, and needing to quietly walk the claim back in a few months once more data arrives, which damages trust more than saying less would have. GLP-1 medications and skin changes are a genuinely important area to watch, and precisely because it matters, I would rather wait for a clearer picture than publish something today that I might need to contradict later.

The commercial pressure to publish anyway

I recognize the incentive to move fast here. GLP-1 medications are a high-search-volume topic, and a practice publishing early captures search traffic before competitors do. I think that incentive is exactly why patience deserves to be stated as a value rather than assumed. Search rankings reward the practice that publishes first. Patient trust rewards the practice that published something durable. Those are not always the same practice, and I would rather be the second one.

What I'm actually waiting for

I want to see whether the dermatologic signal replicates across additional case reports or a larger cohort, whether a plausible mechanism gets proposed and examined, and whether professional dermatology or endocrinology guidance begins to address it directly. Once two or more of those conditions are met, I will write about it, and I will write about it in enough clinical depth to be useful rather than as a reactive headline. Until then, I would rather tell you I am watching it than tell you something I am not yet confident is true.

— Dr. Iryna Lazuk, MD, Lazuk Esthetics, Alpharetta, Georgia